Hematology Advisor
LightNews LightNews
banner
hematologyadvisor.bsky.social
Hematology Advisor
@hematologyadvisor.bsky.social
120 followers 140 following 150 posts
HematologyAdvisor.com is a trusted knowledge base of practical information and resources focused on hematology and critical care medicine.
Posts Replies Media Videos
hematologyadvisor.bsky.social
In patients with severe #aplasticAnemia, upfront allogeneic HCT using alternative donors has become an option for some, but this method has had limited utilization. From @bloodjournals.hematology.org.

https://bit.ly/48bV1FK

#anemia
Use of Alternative Donor HCT Limited in Patients With Severe Aplastic Anemia
In patients with SAA, upfront allogeneic HCT using alternative donors has become an option for some, but this method has had limited utilization.
bit.ly
November 12, 2025 at 4:30 PM
hematologyadvisor.bsky.social
Betty Pace, MD, of Augusta University talks about research to look forward to at the @ash.hematology.org meeting #ASH25.

https://bit.ly/4p3Sjry

#PedHeme #PedOnc
Video: What to Look Forward to at the 2025 ASH Annual Meeting With Betty Pace, MD
Betty Pace, MD, of August University talks about research to look forward to at the American Society of Hematology (ASH) 2025 meeting.
bit.ly
November 11, 2025 at 8:11 PM
hematologyadvisor.bsky.social
@ash.hematology.org President Belinda R. Avalos, MD, shares her perspectives on the past year’s political changes and how they are affecting #hematology research and care.

https://bit.ly/474ugkS

#HemOnc
ASH Works to Support Hematologists, Patients Through Uncertain Political Period
ASH President Belinda R. Avalos, MD, shares perspective on recent political changes and how ASH is supporting hematologists' research.
bit.ly
November 11, 2025 at 8:11 PM
hematologyadvisor.bsky.social
Pretreatment blood signatures in patients with #DLBCL may indicate the likelihood of successful CAR T-cell therapy outcomes and could guide pretherapeutic approaches. Presented at #ESMO25.

https://bit.ly/3Ll4MIU

#lymsm #lymphoma
Pretreatment Immune Composition Influences CAR-T Efficacy in DLBCL
All patients with detectable circulating B cells prior to treatment achieved complete remission.
bit.ly
November 10, 2025 at 6:13 PM
hematologyadvisor.bsky.social
Unlike traditional #Medicare patients, Medicare Advantage enrollees who need major gen/gastro cancer surgery frequently use lower quality hospitals rather than high-quality teaching hospitals. @jamasurgery.com @renalurologynews.bsky.social.

https://bit.ly/4hLzJSA

#gicsm #GCAM
Cancer Surgery at High-Quality Hospitals Less Likely for Medicare Advantage Patients
A US study investigated whether Medicare Advantage plans limit access to high-quality cancer surgery.
bit.ly
November 9, 2025 at 6:39 PM
hematologyadvisor.bsky.social
Once-weekly subcutaneous marstacimab significantly reduced bleeding rates and was well tolerated in male patients with severe #hemophilia A or moderately severe to severe hemophilia B without inhibitors. Published in @bloodjournals.hematology.org.

https://bit.ly/47osaO7
Once-Weekly Marstacimab Reduces Bleeding Rates and Is Well Tolerated in Severe Hemophilia A and B
Marstacimab significantly reduced bleeding rates and was well tolerated in males with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors.
bit.ly
November 8, 2025 at 7:14 PM
hematologyadvisor.bsky.social
In older cancer patients, receiving federal housing assistance is associated with earlier-stage diagnosis of #breastcancer, #colorectalcancer, and #NSCLC. Published in @jamanetworkopen.com and @cancertherapyadv.bsky.social.

https://bit.ly/4oVG9RB

#bcsm
In Older Adults, Federal Housing Assistance Is Linked to Stage of Cancer Diagnosis
In older cancer patients, receiving federal housing assistance is associated with earlier-stage diagnosis of breast cancer, colorectal cancer, and NSCLC.
bit.ly
November 7, 2025 at 7:13 PM
hematologyadvisor.bsky.social
Ultra-low-pass whole genome sequencing of circulating tumor DNA appears to provide important prognostic information regarding patients with #LBCL. Published in @ascopost.bsky.social JCO Precision Oncology and @hematologyadvisor.bsky.social.

https://bit.ly/4nzwSO1

#lymsm #lymphoma
Whole Genome Sequencing Shows High Prognostic Utility in LBCL - Oncology Nurse Advisor
Researchers assessed whether ULP-WGS would have prognostic utility in patients with LBCL.
bit.ly
November 7, 2025 at 7:13 PM
hematologyadvisor.bsky.social
#Oncologist coverage across the US has declined in recent years, leading to #caregaps. Published in @ascopost.bsky.social JCO Oncology Practice and @cancertherapyadv.bsky.social.

https://bit.ly/43dRtjt
Oncologist Care Gaps Affect Rural, Disadvantaged Populations Most
The care gaps are more pronounced among rural populations, and in counties with a higher levels of cancer mortality, health risks, and socioeconomic risks, researchers reported.
bit.ly
November 6, 2025 at 4:12 PM
hematologyadvisor.bsky.social
Once-weekly subcutaneous marstacimab significantly reduced bleeding rates and was well tolerated in male patients with severe #hemophilia A or moderately severe to severe hemophilia B without inhibitors. Published in @bloodjournals.hematology.org.

https://bit.ly/47osaO7
Once-Weekly Marstacimab Reduces Bleeding Rates and Is Well Tolerated in Severe Hemophilia A and B
Marstacimab significantly reduced bleeding rates and was well tolerated in males with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors.
bit.ly
November 5, 2025 at 7:35 PM
hematologyadvisor.bsky.social
Dr. Anderson of UT Southwestern Medical Center in Dallas, Texas, and the lead clinical investigator for the AURIGA study, sat down with us at #IMS2025 to provide more in-depth information on this study and its clinical significance.

https://bit.ly/4hSsrMT

#NDMM #MultipleMyeloma
AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM
Larry Anderson, MD discusses the results from the AURIGA study comparing subcutaneous daratumumab to lenalidomide in patients with NDMM.
bit.ly
November 4, 2025 at 7:43 PM
hematologyadvisor.bsky.social
For patients with #sickleCellDisease presenting to an emergency department during a vaso-occlusive crisis, assignment of an appropriate severity level was associated with a shorter TTFA. Reported in @bloodjournals.hematology.org.

https://bit.ly/47FABU2

#SCD
Appropriate ESI Severity Level Associated With Shorter TTFA for Vaso-Occlusive Crisis in SCD
Researchers determined assignment of an appropriate ESI score was associated with a shorter TTFA for patients with SCD presenting to the emergency department for VOC.
bit.ly
November 4, 2025 at 6:20 PM
hematologyadvisor.bsky.social
Ibrutinib plus rituximab had superior PFS when compared to chemoimmunotherapy among older patients with previously untreated #MCL. Published in @thelancet.com and @cancertherapyadv.bsky.social.

https://bit.ly/48ORgH9

#lymsm
Ibrutinib-Rituximab Outperforms Chemoimmunotherapy in Previously Untreated MCL
Results from the phase 2/3 ENRICH trial support ibrutinib plus rituximab as a “new standard of care option” for first-line treatment of older patients with MCL, researchers wrote.
bit.ly
November 3, 2025 at 6:55 PM
hematologyadvisor.bsky.social
Ibrutinib plus rituximab had superior PFS when compared to chemoimmunotherapy among older patients with previously untreated #MCL. Published in @thelancet.com and @cancertherapyadv.bsky.social.

https://bit.ly/48ORgH9

#lymsm
Ibrutinib-Rituximab Outperforms Chemoimmunotherapy in Previously Untreated MCL
Results from the phase 2/3 ENRICH trial support ibrutinib plus rituximab as a “new standard of care option” for first-line treatment of older patients with MCL, researchers wrote.
bit.ly
November 3, 2025 at 6:55 PM
hematologyadvisor.bsky.social
Researchers developed an ethical framework for allocating gene therapy to patients with #SCD or #TDT. Reported in @bloodjournals.hematology.org.

https://bit.ly/47uPUPv
Researchers Develop Ethics-Based Framework for Allocating Gene Therapies to Patients With SCD or TDT
Researchers developed an ethical framework for allocating gene therapy to patients with SCD or TDT.
bit.ly
November 2, 2025 at 8:09 PM
hematologyadvisor.bsky.social
CTC levels are an independent prognostic factor for patients with transplant-eligible, #NDMM who were treated with a standard-of-care quadruplet regimen. Published in @bloodjournals.hematology.org and @cancertherapyadv.bsky.social.

https://bit.ly/4oHqTYd

#multipleMyeloma
CTCs Show Promise as Prognostic Biomarker in Newly Diagnosed Multiple Myeloma
CTC levels may be prognostic in patients with transplant-eligible, newly diagnosed MM who were treated with a standard-of-care quadruplet regimen.
bit.ly
November 1, 2025 at 9:09 PM
hematologyadvisor.bsky.social
Younger vs older women are more susceptible to changes to their #menstrual cycle after receiving the #COVID19vaccine. Published in @plosone.org and @infectiousdisease.bsky.social.

https://bit.ly/47xqnFt
Adolescent, Young Adult Menstrual Cycles Prolonged After COVID-19 Vaccination
Adolescents and young adults were more susceptible to changes in their menstrual cycle following COVID-19 vaccination compared with older women.
bit.ly
October 31, 2025 at 8:50 PM
hematologyadvisor.bsky.social
A female patient in her 60s was diagnosed with systemic mastocytosis associated with #PCFCL. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/47O33Ew

#lymsm
Primary Cutaneous Follicle Center Lymphoma Associated With Systemic Mastocytosis - Oncology Nurse Advisor
This is likely the first case report on primary cutaneous follicle center lymphoma associated with bone marrow mastocytosis.
bit.ly
October 31, 2025 at 8:50 PM
hematologyadvisor.bsky.social
An elderly man with no prior history of bleeding disorders experienced recurrent acute subdural hematoma following a mild head trauma and was diagnosed with mild congenital #hemophilia A. Published in @cureusmedical.bsky.social and @rarediseaseadvisor.bsky.social.

https://bit.ly/3JsRbyy
Acute Subdural Hematoma in Elderly Patient Diagnosed as Hemophilia
Undiagnosed bleeding disorders should be considered in elderly patients who present with unexplained postoperative hemorrhage.
bit.ly
October 30, 2025 at 3:52 PM
hematologyadvisor.bsky.social
The combination of PTCy and Aba significantly reduced chronic #GVHD and improved GRFS compared with standard tacrolimus and methotrexate prophylaxis in patients undergoing allo-HSCT. Published in @bloodjournals.hematology.org.

https://bit.ly/43A8Zys
Posttransplant Cyclophosphamide Plus Abatacept Reduces Chronic GVHD After Allo-HSCT
PTCy and abatacept significantly reduced chronic GVHD and improved GRFS compared with standard tacrolimus and methotrexate prophylaxis in patients undergoing allo-HSCT.
bit.ly
October 29, 2025 at 7:42 PM
hematologyadvisor.bsky.social
Among a heavily pretreated, older adult population of patients with R/R NPM1m #AML, revumenib was associated with a clinically meaningful response while retaining a safety profile consistent with previous findings. Published in @bloodjournals.hematology.org.

https://bit.ly/4ode7AQ

#leusm
Revumenib Shows Promise in Treating NPM1-Mutated Relapsed/Refractory AML
Researchers determined revumenib showed promising efficacy in patients with R/R NPM1m AML.
bit.ly
October 28, 2025 at 6:20 PM
hematologyadvisor.bsky.social
Single men with #cancer reported feeling overlooked by their #HCPs. Published in @oncologynurseadv.bsky.social.

https://bit.ly/4qocy4w

#cancercare
Single Men With Cancer Have More Negative Experiences With Their HCPs
In focus group interviews, married men with cancer reported better experiences for themselves and their caregivers with healthcare providers, compared with their single counterparts. Married men with cancer reported better experiences for themselves and...
bit.ly
October 27, 2025 at 7:13 PM
hematologyadvisor.bsky.social
Children in the US will have either relied on publicly subsidized insurance or experienced periods without any insurance during the post-ACA, prepandemic policy era. Recent reductions in #Medicaid funding may worsen existing gaps. From @jama.com @clinicalpainadv.bsky.social.

https://bit.ly/4o4svvq
Reduced Medicaid Funding May Worsen Risk for Coverage Gaps in American Children
Key findings on insurance dynamics for American children (post-ACA, prepandemic): 42% ever uninsured, 61% ever on Medicaid/CHIP.
bit.ly
October 26, 2025 at 8:01 PM
hematologyadvisor.bsky.social
TFR is a feasible target for patients with #CML living in low- and middle-income countries, according to research presented at #ESMO25.

https://bit.ly/4727w6m

#leusm
Patients With CML Living in LMICs May Reach High TFR Rates - Hematology Advisor
Researchers evaluated long-term outcomes among patients with CML living in LMICs who received imatinib through financial assistance from the Max Foundation.
bit.ly
October 25, 2025 at 8:53 PM
hematologyadvisor.bsky.social
Many patients with #CLL/#SLL who were intolerant of ibrutinib and/or acalabrutinib were able to tolerate and benefit from zanubrutinib. Published in @bloodjournals.hematology.org.

https://bit.ly/4o0q7Wd

#leusm
Zanubrutinib May Benefit CLL/SLL Patients Intolerant of Other BTK Inhibitors
Researchers determined zanubrutinib may be effective for patients with CLL/SLL who were intolerant to other BTK inhibitors.
bit.ly
October 24, 2025 at 8:45 PM